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The objective of the present study was to develop a simple and selective HPLC method for the 
simultaneous determination of hesperidin (HP), caffeic acid (CA), ferulic acid (FA) and p-coumaric 
acid (p-CA) in rat plasma after intravenous administration of Portulaca oleracea L. extract (POE). With 
the hyperoside as the internal standard, the sample pretreatment procedure involved simple single-step 
extraction with methanol of 0.2 mL plasma. The mobile phase consisted of methanol-acetonitrile-
tetrahydrofuran-0.5% glacial acetic acid (5:3:18:74, v/v/v/v). The calibration curves were linear over 
the range of 0.1-25 μg mL-1, 0.1-25 μg mL-1, 0.1-25 μg mL
-1and 0.015-3 μg mL-1 for HP, CA, FA and 
p-CA, respectively. The method developed was suitable for the pharmacokinetic study of HP, CA, FA 
and p-CA in rats after intravenous administration of POE.
Uniterms: Portulaca oleracea L./pharmacognosy. High Performance Liquid Chromatography/rat plasma. 
Vegetal extract/pharmacokinetic study. Medicinal plants.
O objetivo do estudo foi desenvolver um método simples e específico de HPLC para a determinação 
simultânea de hesperidina (HP), ácido caféico (CA), ácido ferúlico (FA) e ácido p-cumárico (p-CA) em 
plasma de rato após a administração intravenosa de extrato Portulaca oleracea L. (POE) empregando 
hyperosídeo como padrão interno de referência. Metanol foi empregado para os analitos em plasma 
(0,2 mL). A fase móvel isocrática foi composta por metanol-acetonitrila-tetraidrofurano-0,5% ácido 
acético glacial (5:3:18:74, v/v/v/v). Curvas de calibração foram lineares na faixa de concentração 
de 0,1-25 μg mL-1, 0,1-25 μg mL-1, 0,1-25 μg mL-1 e 0,015-3 μg mL-1 para HP, CA, FA e p-CA, 
respectivamente. O método desenvolvido foi adequado para estudo farmacocinético de HP, CA, FA e 
p-CA em ratos após a administração intravenosa de POE.
Unitermos: Portulaca oleracea L./farmacognosia. Cromatografia Líquida de Alta Eficiência/plasma de 
rato. Extrato vegetal/estudo farmacocinético. Plantas medicinais.
INTRODUCTION
Portulaca oleracea L., a well-known traditional Chi-
nese medicine, is used as a treatment for removing heat, 
counteracting toxicity, cooling blood, hemostasia and anti-
dysentery (PRC, 2010). As a widespread and abundant 
plant in the world, Portulaca oleracea L. is also used as 
a folk medicine in many countries. Recently, a number of 
pharmacological studies showed that Portulaca oleracea 
L. had potential activities of relaxing skeletal muscle in 
rat (Parry et al., 1993), analgesic and anti-inflammatory 
(Chan et al., 2000), wood healing effect (Rashed et al., 
2003), meliorating abnormal uterine bleeding (Shobeiri et 
al., 2009), neuropharmacological effect (Radhakrishnan 
et al., 2001) and so forth. In addition, phenolic acids and 
flavone glycosides, being important chemical constituents 
of this plant, have also been reported, such as hesperidin 
(HP), caffeic acid (CA) (Yang et al., 2007), ferulic acid 
(FA) and p-coumaric acid (p-CA) (Xiang et al., 2005). 
Also, these four bioactive compounds proved beneficial to 
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health for the antioxidant effect of FA and CA (Maurya et 
al., 2010), anticancer activity of HP (Lee et al., 2010) and 
by the property of p-CA for inhibiting growth of bacteria 
(Aziz et al., 1998). Thereby, these bioactive constituents 
can be used as marker compounds to characterize the 
Portulaca oleracea L. extract (POE). More recently, some 
in vivo investigations have focused on the pharmacokinet-
ics of individual HP (Jin et al., 2010), FA (Zhang et al., 
2009) and CA (Uang et al., 1997) by the HPLC, LC/MS 
and LC/MS/MS methods, respectively. However, little 
attention has been devoted to the pharmacokinetic study 
of bioactive components in POE. Therefore, the present 
study is the first to report a HPLC method developed and 
validated for simultaneously determination of HP, FA, CA 
and p-CA in rat plasma and its pharmacokinetic study after 
intravenous administration of POE.
MATERIALS AND METHODS
Plant material
Portulaca oleracea L. were collected from Shenyang 
(Liaoning, China) in September 2010, and identified by 
Professor Yanjun Zhai. Voucher specimens (No. 2010090) 
were deposited at the School of Pharmacy, Liaoning Uni-
versity of Traditional Chinese Medicine.
Reagents and chemicals
HP, CA, FA and the internal standard (IS), hypero-
side, were obtained from the National Institute for the Con-
trol of Pharmaceutical and Biological Products (Beijing, 
China). P-CA was provided by Nanchang Beta Biotech 
Co., Ltd. (Nangchang, China). All the chemical structures 
of the four compounds and IS are shown in Figure 1. Water 
was purified with a Milli-Q® Biocel Ultrapure Water Sys-
tem (Millipore, Bedford, MA, USA. Methanol, acetonitrile 
and tetrahydrofuran were all of HPLC grade and provided 
by Damao (Chemical Reagent Plant, Tianjin, China). All 
other reagents were of analytical grade (Jinfeng Chemical 
Factory, Tianjin, China).
Apparatus and chromatographic conditions
The Agilent 1100 series HPLC system (Agilent 
technology, Palo Alto, CA, USA) consisted of a quaternary 
Pump (G1310A), a vacuum degasser (G1322A), a UV/VIS 
spectrophotometric detector (G1314A) and Chemstation 
software (Agilent). An analytical Kromasil C18 column (5 
µm, 150 × 4.6 mm, Sanjie Science and Technologies, Da-
lian, China) connected with a KR C18 guard column (5 μm, 
35 × 8.0 mm, Dalian Create Science and Technology Co., 
Ltd., China) was employed to determine the analytes at 
ambient temperature. The mobile phase consisted of a 
mixture of methanol-acetonitrile-tetrahydrofuran-0.5% 
glacial acetic acid (5:3:18:74, v/v/v/v), which was filtered 
and degassed under reduced pressure before use. The flow 
rate was constantly kept at 1 mL min-1 and chromatograms 
were recorded at 283 nm for HP, 322  nm for FA, CA, IS 
and p-CA, respectively.
Preparation of POE
The dried whole plant of Portulaca oleracea L. 
(5 kg) was extracted with 60% ethanol (50 L) twice by re-
fluxing 2 h, then filtrates were collected and combined, and 
ethanol evaporated under reduced pressure. Subsequently, 
the residue was passed through an AB-8 macroporous resin 
column (10 × 120 cm, Shanghai, China). To eliminate 
impurity, the column was eluted with 20 L water, and with 
50 L of 60% ethanol. After removing the ethanol of 60% 
ethanol fraction in vacuo, the supernatant was dried in a 
water bath. Subsequently, the dried powders (68 g) were 
extracted with methanol by refluxing 1 h, and the solvent 
was recovered under reduced pressure. Following this, the 
FIGURE 1 - Chemical structures of (a) hesperidin, (b) caffeic 
acid, (c) ferulic acid, (d) p-coumaric acid and (e) hyperoside (IS).
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residue was extracted with 50 mL of a mixture of ethanol-
water (5:95, v/v) in an ultrasonic bath for 45 min. The 
supernatants were filtered with a 0.45 μm membrane filter 
and stored at 4 °C prior to use. The prepared solution was 
analyzed by HPLC-UV/VIS. The contents corresponding 
to HP, CA, FA and p-CA were 7.2, 6.7, 24 and 17 μg mL-1, 
respectively.
Preparation of standards and quality control 
samples
Stock solutions of HP, CA, p-CA and IS were pre-
pared by dissolving in methanol to yield concentrations 
of 200, 200, 170, 124 μg mL-1 while FA in 70% methanol 
was 200 μg mL-1, respectively. The combined working 
solutions were prepared with diluted stock solution in 
series to concentrations of 0.4-100 μg mL-1 for HP, CA, 
and FA and also, 0.06-12 μg mL-1 for p-CA. The working 
solution of IS was 12.4 μg mL-1 and obtained by diluting 
stock solution with methanol. All the working solutions 
were stored at 4ºC. Calibrators of HP, CA and FA (0.1, 0.2, 
0.4, 1.0, 2.0, 5.0, 10.0 and 25.0 μg mL-1) and p-CA (0.015, 
0.03, 0.075, 0.3, 0.75 and 3.0 μg mL-1) were prepared by 
adding standard mixture working solutions (50 μL) and 
working solution IS (50 μL), respectively, to 200 μL drug-
free rat plasma. The quality control (QC) samples were 
prepared at low, middle and high concentrations (0.25, 
12.5 and 20 μg mL-1 for HP, 0.25, 12.5 and 20 μg mL-1 for 
CA, 0.25, 12.5 and 20 μg mL-1for FA and 0.04, 1.5 and 
2.4 μg mL-1 for p-CA) in bulk, and aliquots were stored at 
-20 °C until analysis.
Plasma extraction
Before deproteinating, 20 μL of acetic acid, 50 μL of 
IS were added to 200 μL plasma. The proteins of plasma 
were precipitated with 1 mL methanol, followed by vortex 
mixing for 1 min and then centrifuged at 890 g for 15 min. 
The supernatant was collected and evaporated to dryness 
at 40 ºC under a stream of nitrogen. The residue was then 
dissolved in 200 μL of mobile phase, and centrifuged at 
15,092 g for 10 min. The injection volume of supernatant 
was 20 μL for analysis.
METHOD VALIDATION
Selectivity
The selectivity was determined by comparing 
chromatograms of different blank plasma obtained from 
rat with those of corresponding standard plasma samples 
spiked with HP, FA, CA, p-CA and IS and plasma sample 
after intravenous administration of POE.
Linearity, LOD and LOQ
Linearities were evaluated over the concentration 
range of 0.1-25, 0.1-25, 0.1-25 and 0.015-3 μg mL-1 for 
HP, CA, FA and p-CA, respectively. The calibration curves 
were prepared by exact concentrations of working solu-
tions added to blank plasma and established by weighted 
(1/c2) least square linear regression analysis based on the 
peak area ratio of each analyte to the internal standard. The 
limit of detection (LOD) and the limit of quantification 
(LOQ) were defined as the lowest concentration of each 
analyte and determined by a signal-to-noise ratio of 3 and 
10 with an acceptable accuracy (RE %) within ±20% and 
a precision (RSD %) that did not exceed 20%.
Precision and accuracy
The validation of intra-day precision and accuracy 
were evaluated with replicates of QC plasma samples at 
the three concentration levels on the same day as well as 
inter-day precision on each day for 3 separate days. The 
intra-day and inter-day precision was defined as the rela-
tive standard deviation (RSD) and accuracy was deter-
mined by calculating the relative error (RE).
Extraction recovery
The extraction recoveries of HP, CA, FA and p-CA 
were determined by comparing the peak area of each 
compound from QC samples that were at the three con-
centrations low, middle and high, to that of the unextracted 
standard solutions containing the equivalent amount of 
analytes (n = 6).
Stability
Stability was investigated at low, middle and high 
concentrations of QC samples. A short-term stability ex-
periment was carried out at ambient temperature (25 °C) 
for 24 h whereas long-term stability was tested by storage 
at -20 °C for 1 month, respectively. QC samples were sub-
jected to three freeze (-20 °C)-thaw (room temperature) 
cycles to determine freeze-thaw stability.
Animals and pharmacokinetic study
Male Wistar rats (body weight 250-300 g) were 
provided by the Laboratory Animal Center of Liaoning 
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University of Traditional Chinese Medicine (Shenyang, 
China). Before the experiments, all rats were kept in a 
controlled environment for 1 week and had free access 
to standard laboratory food and water intake. The rats 
were fasted 12-16 h prior to administration of the POE. 
Animal experiments were carried out in accordance with 
the Guidelines for Animal Experimentation of Liaoning 
University of Traditional Chinese Medicine, and the pro-
cedure was approved by the Animal Ethics Committee of 
the institution.
Five rats were administered POE solution via tail 
vein injection at a dose of 11 mL kg-1 (approximately 
equivalent to 0.1 mg kg-1 of HP, 0.14 mg kg-1 of CA, 
0.25 mg kg-1 of FA and 0.2 mg kg-1 of p-CA, respectively). 
Blood samples (0.4 mL) from orbital sinus were taken into 
heparinized tubes at times of 5, 10, 15, 20, 25, 30, 45, 60, 
90, 150, 210, 270 min after dosing, and then centrifuged at 
890 g for 15 min, immediately. Plasma was then trans-
ferred into clean test tubes and stored at -20 ºC until 
analysis.
RESULTS AND DISCUSSION
Method development
Good separations and suitable retention time of 
four analytes were obtained in isocratic elution using an 
analytical Kromasil C18 column (5 µm, 150 × 4.6 mm, 
Sanjie Science and Technologies, Dalian, China) with 
mobile phase consisting of methanol-acetonitrile-
tetrahydrofuran-0.5% glacial acetic acid (5:3:18:74, 
v/v/v/v) after various mixtures of methanol, acetonitrile, 
tetrahydrofuran water solution solutions were used. The 
addition of 0.5% glacial acetic acid in the solvent system 
led to the sharp peak shapes. Moreover, to simultaneously 
determine four analytes, use of wavelengths ranging from 
280 to 330 nm was attempted. Stronger signals were 
only observed when the wavelength was set at 283 nm 
for HP and 322 nm for CA, FA and p-CA, respectively. 
Vitexin-4”-O-glucoside, vitexin-2”-O-rhamnoside and 
baicalin had been considered as IS, the retention time of 
these, however, proved unsuitable due to the presence 
of interference by endogenous materials. Ultimately, 
hyperoside, given its similar chromatographic behavior 
to the analytes, was chosen as the internal standard for 
the assay. To improve the solution of analytes, a mixture 
of ethanol-water (5:95, v/v) 50 mL was used to extract 
residue in the ultrasonic bath during the preparation of 
POE. The sample pretreatment was also optimized by 
precipitation of protein with methanol and addition of 
20 μL acetic acid to the plasma.
Method validation
The typical chromatograms of blank plasma, 
plasma spiked with analytes and IS are shown in Figure 
2A and 2B, respectively. The chromatogram obtained 
from plasma samples after intravenous administration is 
shown in Figure 2C and the result indicated the absence 
of interfering endogenous peaks observed at the retention 
time of analytes. The retention times of HP, CA, FA, IS 
and p-CA were approximately 7.31, 8.68, 10.04, 11.72 and 
12.72 min, respectively. The total run time was 14.0 min.
Eight-point calibration curves over the concentra-
tion range of 0.1-25 μg mL-1for HP, CA and FA, and six-
point 0.015-3 μg mL-1 for p-CA, respectively, were used 
to evaluate the linearity. The weighted (1/c2) least squares 
FIGURE 2A - Representative chromatogram of blank plasma.
FIGURE 2B - Representative chromatogram of plasma spiked 
with hesperidin, caffeic acid, ferulic acid, p-coumaric acid and IS.
FIGURE 2C - Representative chromatogram of plasma sample 
after 5 min intravenous administration of POE.
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linear regression was employed to obtain the regression 
equations: typically y = 0.6192x + 0.038 (r = 0.9985, HP), 
y = 0.0482x - 0.0193 (r = 0.9979, CA), y = 0.1026x - 0.0374 
(r = 0.9981, FA), y = 5.1443x - 0.0664 (r = 0.9968, p-CA).
The limits of quantification (LOQ, S/N = 10) 
for HP, CA, FA and p-CA were 0.11, 0.105, 0.12 and 
0.014 μg mL-1, respectively, whereas the limits of de-
tection (LOD, S/N = 3) were 0.035, 0.031, 0.036 and 
0.003 μg mL-1 for HP, CA, FA and p-CA, respectively.
The data for intra- and inter-day precision at the 
three concentrations ranged from 0.5 to 12.5%, and RE 
were -4.7 to 2.0%, which conform to the criteria for the 
analysis of biological sample according to guidance of 
FDA (USFDA. 2001). 
Mean extraction recoveries at three concentration 
levels for HP, CA, FA and p-CA were 90.87%, 92.64%, 
96.75%, and 93.72%, respectively, and the RSD had a 
range of 6.4-8.5%, suggesting negligible loss during 
extraction. 
The short-term, long-term and freeze-thaw stabil-
ity of analytes in plasma ranged from 93.49 to 99.95%, 
indicating no significant degradation occurred during 
chromatography, extraction and sample storage processes.
Application to pharmacokinetic study
Pharmacokinetic analysis was performed with 3p97 
(Practical Pharmacokinetic Program, 1997, China) to 
calculate the relevant parameters by both compartment 
and non-compartment approaches. Moreover, terminal 
half-life (t1/2) was defined as t1/2 = 0.693/λz and the terminal 
elimination rate, λz, was calculated by natural logarithms 
of linear regression on the last five points.
According to AIC and R2 (Table I), a two-compart-
ment open model (Weight = 1) yielded the best fit to the 
plasma concentration-time curves for HP, CA and p-CA, 
and one-compartment open model (Weight = 1/c2) was 
optimal for FA, respectively. The plasma concentration 
profiles and pharmacokinetic parameters of HP, CA, FA 
and p-CA in rat plasma after intravenous administration 
of POE are illustrated in Figure 3 and Table II. The results 
showed that the apparent volume of distribution (Vc) of 
FA was larger than other analytes, suggesting a wider 
distribution of FA in the body. Furthermore, all half-lives 
TABLE I - AIC and R2 data of hesperidin, caffeic acid, ferulic acid and p-coumaric acid
model weight
HP CA FA p-CA
AIC R2 AIC R2 AIC R2 AIC R2
1 1 -24.6 0.91 -19.6 0.93 -9.16* 0.94 -23.8 0.97
2 1 -39.3* 0.99 -45.9* 0.99 -9.13 0.96 -34.6* 0.99
3 1 -35.4 0.99 -41.5 0.99 -5.13 0.96 -30.1 0.99
1 1/c -12.3 0.60 -11.1 0.79 1.52 0.84 -18.5 0.95
2 1/c -30.5 0.97 -40.3 0.99 -5.68 0.94 -20.8 0.97
3 1/c -26.9 0.97 -36.8 0.99 -1.48 0.94 -17.0 0.97
1 1/c2 -2.20 0.40 -5.60 0.58 8.90 0.67 1.3 0.62
2 1/c2 -21.4 0.92 -37.0 0.99 -2.04 0.92 -2.8 0.85
3 1/c2 -17.3 0.92 -30.8 0.99 1.97 0.92 -1.2 0.32
1 1 -14.2 0.91 -9.5 0.99 3.86 0.93 -14.1 0.97
2 1 -31.5 0.99 -42.1 0.99 3.72 0.95 -26.5 0.99
3 1 -28.7 0.99 -38.1 0.88 7.86 0.95 -22.3 0.99
1 1/c -4.40 0.73 -4.6 0.99 -0.17 0.95 -13.7 0.97
2 1/c -26.4 0.98 -39.6 0.99 -0.83 0.97 -15.4 0.98
3 1/c -24.5 0.98 -33.3 0.99 2.82 0.97 -14.3 0.99
1 1/c2 2.90 0.39 -2.5 0.86 -2.45 0.96 8.8 0.79
2 1/c2 -17.6 0.96 -32.2 0.99 1.66 0.97 -3.8 0.96
3 1/c2 -19.8 0.98 -33.9 0.99 3.32 0.97 0.56 0.96
* Representation of best fit result of AIC for each group, based on least value. AIC denotes Akaike’s Information Criterion, 
AIC=NlnRe+P (N represents data of point, Re is residual sum of squares, P refers to parameter member of model), and R2 is square 
of Re.
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TABLE II - Pharmacokinetic parameters of hesperidin, caffeic acid, ferulic acid and p-coumaric acid in rat plasma (mean ± SD, 
n = 5) after intravenous administration of POE
Parameter (Units) HP CA FA p-CA
Dose (mg/kg) 0.1 0.14 0.25 0.2
Vc (L/kg) 0.0442 ± 0.0063 0.0410 ± 0.0040 0.0778 ± 0.0021 0.0442 ± 0.023
T1/2ke (min) - - 62.90 ± 0.53 -
T1/2α (min) 5.69 ± 1.94 5.50 ± 0.60 - 3.97 ± 0.93
T1/2β (min) 62.66 ± 1.57 51.32 ± 2.08 - 23.38 ± 2.79
aAUC0→t (mmol·min /L) 0.11 ± 0.02 0.45 ± 0.49 1.51 ±0.71 0.52 ± 0.67
CL (kg·L/ min) 0.0014 ± 0.007 0.0017 ± 0.0007 0.0008 ± 0.0006 0.0023 ± 0.0007
MRT0→t
(min) 43.95 ± 0.93 38.69 ± 1.68 81.25 ± 0.11 28.46 ± 0.17
bAUC0→t (mmol·min /L) 0.08 ± 0.12 0.40 ±0.33 1.58 ± 0.87 0.50±0.05
T1/2z (min) 99.606 ± 0.013 40.7435 ± 1.34 65.5490 ± 6.07 39.906 ±14.20
a
 data calculated by compartmental approach and b non-compartmental approach. Vc is apparent volume of distribution; T1/2ke, 
T1/2α, T1/2β, are all half-life parameters, representing half-life of central compartment, absorption and distribution phase, respectively, 
T1/2z is terminal half-life; AUC is area of under curve; MRT is mean residence time.
of HP, CA and p-CA were shorter than their respective 
β half-lives, which indicated that HP, CA and p-CA pre-
sented a rapid distribution phase and a more prolonged 
elimination phase. A shorter T1/2z of HP was obtained in our 
investigation, compared with values in earlier literature, 
indicating that HP suffered more rapid elimination than its 
FIGURE 3 - Mean plasma concentration-time of (a) hesperidin, (b) caffeic acid, (c) ferulic acid and (d) p-coumaric acid in rats 
after intravenous administration of POE.
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individual form (Li, et al., 2008). Moreover, both α half-
life and β half-life of CA in this study were longer than 
previously reported values after intravenous administra-
tion of individual drug at higher dose (Uang, et al., 1997). 
This phenomenon may be ascribed to the coexisting effect 
of multiple components in POE. In addition, the plasma 
concentration profiles of FA exhibited a second peak 
after intravenous administration of POE at 0.5 h, which 
presented a different pharmacokinetic process compared 
with individual FA (Zhang, et al., 2009). CA was able to 
be enzymatically converted to FA in hepatocytes, and FA 
being an O-methylated product of CA was reabsorbed in 
blood (Moridani et al., 2002), which accounted for the 
second peak. Possibly, the coexisting constituents in POE 
impacts on the pharmacokinetic behavior of FA. Given 
the diverse groups of compounds present in POE, the 
pharmacokinetic character of our target compounds may 
be interactively affected by other coexisting components, 
either due to competition of drug carrier in transportation 
between them, or because the activity of enzymes, such as 
CYP450s, was prompted or inhibited by other coexisting 
constituents during metabolism.
CONCLUSIONS
The present article described the development and 
validation of an HPLC method for the simultaneous de-
termination of HP, CA, FA and p-CA in rat plasma, which 
can play an important role in clarifying the mechanism of 
action and efficacy of POE via the pharmacokinetic study 
of the four bioactive constituents.
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